Tao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tao Wang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jinfu Zhang
Department of Liver Surgery and Liver Transplantation Center, West China Hospital of Sichuan University, 610041, Chengdu, Sichuan, China
2 shared publications - Liangliang Xu
Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University
2 shared publications - Mingqing Xu
Department of Liver Surgery and Liver Transplantation Center, West China Hospital of Sichuan University, 610041, Chengdu, Sichuan, China
2 shared publications - Ming Zhang
Department of Liver Surgery and Liver Transplantation Center, West China Hospital of Sichuan University, 610041 Chengdu, Sichuan, China
1 shared publication - Peng Wang
Department of Liver Surgery and Liver Transplantation Center, West China Hospital of Sichuan University, 610041 Chengdu, Sichuan, China
1 shared publication - Wentao Wang
Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China
1 shared publication
Latest Publications
- 1 May 2023
- Vol. 54 (3) , 692-698
肝细胞癌免疫治疗的现状及发展
肝癌是一种严重的全球健康问题，也是常见的癌症相关死亡原因。肝细胞癌（hepatocellular carcinoma, HCC）是肝癌常见的病理类型。早期HCC临床症状不明显，50%的HCC患者确诊时已处于晚期。系统全身治疗被推荐用于晚期HCC。随着分子靶向药物（索拉非尼、仑伐替尼）的发展，晚期HCC的系统全身治疗取得了一定进展，但对HCC患者生存获益仍然不大。近年来，免疫检查点抑制剂的出现改变了HCC治疗的格局，为HCC精准治疗提供了更多的可能性并展现出较好的效果。特别是阿替利珠单抗和贝伐珠单抗的联合疗法显著改善了HCC患者的生存预后，此外，过继性细胞疗法、肿瘤疫苗、溶瘤病毒和非特异性免疫治疗也已成为免疫治疗策略。本文就HCC免疫治疗的现状及发展进行概述。
- 1 May 2023
- Vol. 54 (3) , 692-698
肝细胞癌免疫治疗的现状及发展
肝癌是一种严重的全球健康问题，也是常见的癌症相关死亡原因。肝细胞癌（hepatocellular carcinoma, HCC）是肝癌常见的病理类型。早期HCC临床症状不明显，50%的HCC患者确诊时已处于晚期。系统全身治疗被推荐用于晚期HCC。随着分子靶向药物（索拉非尼、仑伐替尼）的发展，晚期HCC的系统全身治疗取得了一定进展，但对HCC患者生存获益仍然不大。近年来，免疫检查点抑制剂的出现改变了HCC治疗的格局，为HCC精准治疗提供了更多的可能性并展现出较好的效果。特别是阿替利珠单抗和贝伐珠单抗的联合疗法显著改善了HCC患者的生存预后，此外，过继性细胞疗法、肿瘤疫苗、溶瘤病毒和非特异性免疫治疗也已成为免疫治疗策略。本文就HCC免疫治疗的现状及发展进行概述。
- Open Access
- 1 January 2021
- Published by Elsevier in Asian Journal of Surgery
- Vol. 44 (1) , 423-424
Thrombocytopenia predicts the prognosis of hepatocellular carcinoma patients with Ishak score 6 after hepatectomy: A propensity score matching analysis
- 1 January 2021
- Published by Elsevier in Asian Journal of Surgery
- Vol. 44 (1) , 423-424
Open AccessThrombocytopenia predicts the prognosis of hepatocellular carcinoma patients with Ishak score 6 after hepatectomy: A propensity score matching analysis